VisionGate, Inc

VisionGate, Inc., is a breakthrough liquid-biopsy technology company, leading the battle against lung cancer through early detection technology with a simple, non-intrusive sputum test. The foundation for our diagnostics capability is the proprietary Cell-CT™ 3-Dimensional Cell Imaging and Analysis platform. The Cell-CT platform, using a process called optical computed tomography (CT), produces 3D images of individual cells with the ability to morphologically recognize over 700 structural biomarkers of normal and abnormal cells. The Cell-CT platform can process any liquid biopsy specimen and therefore has potential applicability to detect a wide range of different cancers and cancer biosignatures that could aid in identifying potential treatments using targeted pharmaceutical therapies.